Regulation of IgE responses by B cell receptor signaling
Project Number5R01AI130470-03
Contact PI/Project LeaderALLEN, CHRISTOPHER DAVID CABALLERO
Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
Project Summary/Abstract
Allergic diseases, including asthma, allergic rhinitis, and food allergy, have been steadily increasing in
incidence and disproportionately affect children. Allergic responses can be triggered rapidly upon exposure to
an allergen that binds to IgE antibodies on mast cells and basophils; these cells then degranulate and release
potent pro-inflammatory mediators. If this response occurs systemically, known as anaphylaxis, it can be life-
threatening. However, despite the importance of IgE in allergic disease, the intrinsic mechanisms that regulate
IgE-expressing B cells remain unclear. Recent technical advances have made it possible to directly detect and
visualize IgE+ B cells in mice, revealing that IgE+ B cells undergo an abortive germinal center phase and are
predisposed to differentiate into short-lived plasma cells. These properties of IgE+ B cells restrain IgE
responses and therefore may help protect against allergy and anaphylaxis in healthy individuals. Recent
studies have demonstrated that the distinct features of mouse IgE+ B cells are largely due to the expression of
the membrane IgE B cell receptor, which has weak, chronic signaling activity compared with other isotypes.
The overall objective of this study is to determine how B cell receptor signaling regulates IgE+ B cell responses
in mice and whether these findings are applicable to human B cells. The specific goals of this study are to 1)
elucidate the mechanisms by which B cell receptor signaling regulates IgE plasma cell responses, 2) to
characterize the role of B cell receptor signaling in the dynamics of IgE+ B cells in germinal centers, and 3) to
determine whether human IgE B cell receptors regulate IgE responses in a similar fashion to mouse IgE B cell
receptors. The results from these studies will help us understand how potent IgE-mediated allergic responses
are controlled at a molecular level.
.
Public Health Relevance Statement
Project Narrative
Allergic diseases are growing in prevalence worldwide and represent a major public health burden. IgE
antibodies play a key role in triggering allergic responses, yet the mechanisms controlling IgE production
remain poorly understood. In this project, we will study how molecular signals regulate the fate of the B cells
that produce IgE.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AffectAffinityAllergensAllergic DiseaseAllergic ReactionAllergic rhinitisAnaphylaxisAntibodiesAntigensAsthmaB-LymphocytesBasophilsBindingCell Culture TechniquesCellsCharacteristicsChildChronicExposure toFood HypersensitivityGoalsHumanHypersensitivityIgEIncidenceIndividualInflammation MediatorsLaboratoriesLifeLongevityMediatingMembraneMolecularMusPhasePlasma CellsPlayPredispositionPrevalenceProceduresProductionPropertyPublic HealthReactionReceptor SignalingReceptors, Antigen, B-CellRegulationReporterRoleSerumSignal PathwaySignal TransductionSourceStructure of germinal center of lymph nodeVariantWorkallergic responsemast cellplasma cell differentiationresponse
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
20-November-2017
Project End Date
31-October-2022
Budget Start Date
01-November-2019
Budget End Date
31-October-2020
Project Funding Information for 2020
Total Funding
$396,250
Direct Costs
$250,000
Indirect Costs
$146,250
Year
Funding IC
FY Total Cost by IC
2020
National Institute of Allergy and Infectious Diseases
$396,250
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI130470-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI130470-03
Patents
No Patents information available for 5R01AI130470-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI130470-03
Clinical Studies
No Clinical Studies information available for 5R01AI130470-03
News and More
Related News Releases
No news release information available for 5R01AI130470-03
History
No Historical information available for 5R01AI130470-03
Similar Projects
No Similar Projects information available for 5R01AI130470-03